Literature DB >> 6274032

[Tiapride in the treatment of neurological and psychiatric disorders in the elderly (author's transl)].

G Miletto, M Julou.   

Abstract

One hundred patients, aged between 60 and 92 years, were treated with tiapride for neurological disorders (abnormal movements, buccofacial dyskinesias, dopa therapy complications, ballism, eyelid tics, senile tremor, post-traumatic headache, delirium tremens), psychiatric disorders with more or less marked agitation and of various types (hysteria, depression, mood disturbances, hypochondria, delusions, hallucinations), or for mental deficiency, senile dementia, or arteriopathic dementia. Results were excellent, being satisfactory in 70 p. cent, and even more marked in some groups. Tolerance was very good, with some rare cases of somnolence. The efficacy and safety of tiapride makes it of particular value for treating neuropsychiatric disorders in geriatric patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274032

Source DB:  PubMed          Journal:  Sem Hop


  4 in total

1.  Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

Authors:  R A Roos; E J de Haas; O J Buruma; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Release hallucinations and tiapride.

Authors:  R Badino; M Trucco; A Caja; I Del Conte; C Guida; M Ivaldi
Journal:  Ital J Neurol Sci       Date:  1994-05

3.  Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia.

Authors:  R A Roos; E A Van der Velde; O J Buruma; F A de Wolff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

Review 4.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.